In March 2025, SFA Therapeutics announced that two head-to-head preclinical studies of its oral psoriasis therapy candidate, ...
Yuflyma is a TNF blocker approved as a citrate-free, high-concentration, interchangeable biosimilar to Humira (adalimumab).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback